Effect analysis of Adefovir dipivoxil and Entecavir in treatment of chronic hepatitis B patients with positive HBeAg

Objective To evaluate the effect of Adefovir Dipivoxil and Entecavir in treatment of patients with HBeAg-positive chronic hepatitis B.Methods Sixty cases of chronic hepatitis B patients with positive HBeAg were randomly divided into study group and control group,30 patients in study group were treated with Entecavir 0.5 mg,oral per night,30 patients of control group were treated with Adefovir 10 mg,oral one time a day.Both groups were treated for one year and then the therapeutic effect was observed.Results The data of sex,age,ALT,HBV-DNA level of two groups before treatment were not significantly different(P 0.05);HBeAg negative rate,HBeAg seroconversion rates of study group were higher after 6 and 12 months treatment than those of control group,the differences were statistically significant(P 0.05),but there was no significant difference in ALT normalization rate between the two groups after 6 and 12 months treatment(P 0.05);after 12 months treatment,patients with HBV DNA less than 103 copies/ml in two groups had significant difference(P 0.05);there was no significant adverse drug reactions,drug stoping,and the function of blood and kidney were normal after 12 months treatment.Conclusion The efficacy of Entecavir in treatment of chronic hepatitis B patients with positive HBeAg is good,it is available for first-line anti-viral treatment of chronic hepatitis.